List view / Grid view
AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company.
In 2013, it moved its headquarters to Cambridge, United Kingdom, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015, it was the eighth-largest drug company in the world based on sales revenue.
AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).
8 January 2014 | By AstraZeneca
Both companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology...
19 December 2013 | By AstraZeneca
Global agreement strengthens AstraZeneca’s commitment to diabetes, a key growth platform in a core strategic area for the company...
17 December 2013 | By
AstraZeneca is aware of reports that an 505(b)(2) NDA esomeprazole strontium product has been launched in the US by Hanmi Pharmaceutical and affiliates...
In this Screening In-Depth Focus: Technological and sociological advances in HTS: evolution and revolution?; Flow cytometry as a drug screening platform; Show Preview: High-Content Analysis 2014
Preclinical cancer models allow us to gain insight into therapeutic potential and mechanism of anti-cancer agents early in the drug discovery process. Whilst traditional array-based approaches have made a significant contribution to the characterisation of these models, the advent of next generation sequencing has revolutionised genomic research and is anticipated…
13 December 2013 | By AstraZeneca
Lesinurad is an investigational agent being studied as a selective uric acid re-absorption inhibitor that inhibits the URAT1 transporter...
12 December 2013 | By AstraZeneca
Advisory Committee recommends metreleptin for the treatment of paediatric and adult patients with generalised lipodystrophy...
12 December 2013 | By AstraZeneca
Dapagliflozin is being reviewed by the FDA for use as monotherapy, and in combination with other antidiabetic agents...
9 December 2013 | By AstraZeneca
The donation of the facility and its equipment will ensure that the laboratory continues to serve scientific and research purposes...
4 December 2013 | By AstraZeneca
AstraZeneca announced a ruling by the US District Court for the Southern District of New York which ordered Apotex Corp., Apotex, Inc and Torpharm, Inc...
22 November 2013 | By AstraZeneca
Xigduo™ combines dapagliflozin (tradename Forxiga®), a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2), and metformin hydrochloride in a twice daily tablet...
19 November 2013 | By AstraZeneca
AstraZeneca announced that it has selected architects Herzog & de Meuron to design its new centre...
19 November 2013 | By AstraZeneca
The NDA filing was based on comprehensive data from the core Phase III KODIAC programme...
11 November 2013 | By AstraZeneca
Zoladex has been manufactured at AstraZeneca’s Macclesfield plant for over 25 years, supplying the medicine to more than one hundred markets around the world...
"Following a thorough and extensive search it became clear that Marc possessed the rare blend of financial, business and science experience..."
